Bernstein analyst Bruno Monteyne downgrades Beiersdorf (OTC:BDRFY) from Market Perform to Underperform.
Atossa Therapeutics Announces Dosing Completed In Part C of Atossa’s Phase 1/2a Study Of AT-H201 In Healthy Volunteers
Atossa Therapeutics, Inc. (NASDAQ:ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current